Abstract
The efficacy of all chemotherapeutic agents is limited by the occurrence of drug resistance. To further understand resistance to topoisomerase II inhibitors, 50 sublines were isolated as single clones from parental cells by exposure to VP–16 (etoposide) or mAMSA (m–amsacrine). Subsequently, a population of cells from each subline was exposed to three–fold higher drug concentrations allowing 16 stable sublines to be established at higher extracellular drug concentration. Finally, 66 sublines were picked up. The frequency and nature of mutations in the topoisomerase II gene in the drug–selected cell lines were evaluated. In order to screen a large number of cell lines, an RNAse protection assay was developed and mismatches were observed in 13.6% of resistant cell lines (12% of resistant cell lines exposed to lower drug concentrations and 18.8% of resistant cell lines exposed to higher drug concentrations). Some of these mutations are located in vital regions of topoisomerase II (phosphorylation sites in the C–terminal or N–terminal, and nuclear localizing signal of topoisomerase II). Our findings suggest that mutations of topoisomerase II gene are an important and frequent mechanism of resistance to topoisomerase II inhibitors.
Keywords: Topoisomerase II, Mutation, Drug resistance, Multidrug resistance ‐ Chemotherapy
Full Text
The Full Text of this article is available as a PDF (246.6 KB).
REFERENCES
- 1. ) Berger , J. C. , Gamblin , S. J. , Harrison , S. C. and Wang , J. C.Structure and mechanism of DNA topoisomerase II . Nature , 379 , 225 – 232 ( 1996. ). [DOI] [PubMed] [Google Scholar]
- 2. ) Takano , H. , Kohno , K. , Matsuo , K. , Matsuda , T. and Kuwano , M.DNA topoisomerase targeting antitumor agents and drug resistance . Anticancer Drugs , 3 , 323 – 330 ( 1992. ). [DOI] [PubMed] [Google Scholar]
- 3. ) Wells , N. J. , Addison , C. M. , Fry , A. M. , Ganapathi , R. and Hickson , I. D.Serine 1524 is a major site of phosphorylation on human topoisomerase 11α protein in vivo and is a substrate for casein kinase II in vitro . J. Biol. Chem. , 270 , 29746 – 29751 ( 1994. ). [PubMed] [Google Scholar]
- 4. ) Melton , D. A. , Krieg , P. A. , Rebagliati , M. R. , Maniatis , T. , Zinn , K. and Green , M. R.Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter . Nucleic Acids Res. , 12 , 7035 – 7056 ( 1984. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. ) Mickley , L. A. , Bates , S. E. , Richert , N. D. , Currier , S. , Tanaka , S. , Foss , F. , Rosen , N. and Fojo , T.Modulation of the expression of a multidrug resistance gene (mdr–1/P–gly–coprotein) by differentiating agents . J. Biol. Chem. , 264 , 18031 – 18040 ( 1989. ). [PubMed] [Google Scholar]
- 6. ) Matsumoto , Y. , Takano , H. , Kunishio , K. , Nagao , S. and Fojo , T.Expression of drug resistance genes in VP–16 and mAMSA–selected human carcinoma cells . Jpn. J. Cancer Res. , 92 , 778 – 784 ( 2001. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. ) Matsumoto , Y. , Takano , H. , Kunishio , K. , Nagao , S. and Fojo , T.Hypophosphorylation of topoisomerase 11α in etoposide (VP–16)–resistant human carcinoma cell lines associated with carboxy–terminal truncation . Jpn. J. Cancer Res. , 92 , 799 – 805 ( 2001. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. ) Ishida , R. , Iwai , M. , Marsh , K. L. , Austin , C. A. , Yano , T. , Shibata , M. , Nozaki , N. and Hara , A.Threonine 1342 in human topoisomerase 11α is phosphorylated throughout the cell cycle . J. Biol. Chem. , 271 , 30077 – 30082 ( 1996. ). [DOI] [PubMed] [Google Scholar]
- 9. ) Alghisi , G. C. , Roberts , E. , Cardenas , M. E. and Gasser , S. M.The regulation of DNA topoisomerase II by casein kinase II . Cell. Mol. Biol. Res. , 40 , 563 – 571 ( 1994. ). [PubMed] [Google Scholar]
- 10. ) Wells , N. J. , Fry , A. M. , Guano , R , Norbury , C. and Hickson , I. D.Cell cycle phase–specific phosphorylation of human topoisomerase Hoc . J. Biol. Chem. , 269 , 28357 – 28363 ( 1995. ). [DOI] [PubMed] [Google Scholar]
- 11. ) Matsumoto , Y. , Takano , H. and Fojo , T.Cellular adaptation to drug exposure: evolution of the drugresistant phenotype . Cancer Res. , 57 , 5086 – 5092 ( 1997. ). [PubMed] [Google Scholar]
- 12. ) Matsumoto , Y. , Matsumoto , M. , Minemura , M. , Takano , H. , Nagao , S. , Iglesias , A. and Fojo , T.Expression of ATP binding cassette superfamily (multidrug resistance–1, multidrug resistance–associated protein, human canalicular multi–specific organ anion transporter) mRNA in etoposide and m–AMSA resistant cell lines . Jpn. J. Cancer Chemother. , 24 , 1941 – 1946 ( 1997. ). [PubMed] [Google Scholar]
- 13. ) Matsumoto , Y. , Takano , H. , Nagao , S. , Iglesias , A. and Fojo , T.Expression of DNA topoisomerases (I, II alpha, II beta) mRNA in etoposide– and mAMSA–resistant cell lines . Jpn. J. Cancer Chemother. , 24 , 2265 – 2269 ( 1997. ). [PubMed] [Google Scholar]
- 14. ) Liu , Y. , Hsiung , Y. , Jannatipour , M. , Yeh , Y. and Nitiss , J. L.Yeast topoisomerase II mutants resistant to anti–topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide . Cancer Res. , 54 , 2943 – 2951 ( 1994. ). [PubMed] [Google Scholar]
- 15. ) Pepperkok , R. , Lorenz , P. , Ansorge , W. and Pyerin , W.Casein kinase II is required for transition of GO/G1, early Gl, and Gl/S phase of the cell cycle . J. Biol. Chem. , 269 , 6986 – 6991 ( 1994. ). [PubMed] [Google Scholar]